XML 89 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) (USD $)
In Millions, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 29, 2014
Jun. 30, 2013
Jun. 29, 2014
site
Jun. 30, 2013
Restructuring Cost and Reserve [Line Items]        
Restructuring and related cost, expected number of sites exited     10  
Restructuring and related cost, expected cost     $ 3,200  
Restructuring charges(a):        
Employee terminations 17 [1] 136 [1] 47 [1] 115 [1]
Asset impairments 13 [1] 12 [1] 19 [1] 115 [1]
Exit costs 36 [1] 2 [1] 40 [1] 15 [1]
Total restructuring charges 66 [1] 150 [1] 106 [1] 245 [1]
Integration costs(b) 15 [2] 33 [2] 33 [2] 69 [2]
Restructuring charges and certain acquisition-related costs 81 183 139 314
Total additional depreciation––asset restructuring 102 [3] 69 [3] 176 [3] 204 [3]
Implementation costs recorded in our condensed consolidated statements of income as follows(d):        
Total implementation costs 76 [4] 46 [4] 108 [4] 85 [4]
Total costs associated with acquisitions and cost-reduction/productivity initiatives 259 298 423 603
Cost of Sales [Member]
       
Restructuring charges(a):        
Total additional depreciation––asset restructuring 72 [3] 58 [3] 146 [3] 91 [3]
Implementation costs recorded in our condensed consolidated statements of income as follows(d):        
Total implementation costs 22 [4] 5 [4] 28 [4] 11 [4]
Selling, General and Administrative Expenses [Member]
       
Restructuring charges(a):        
Total additional depreciation––asset restructuring 1 [3] 8 [3] 1 [3] 19 [3]
Selling Informational And Administrative Expenses [Member]
       
Implementation costs recorded in our condensed consolidated statements of income as follows(d):        
Total implementation costs 38 [4] 34 [4] 53 [4] 65 [4]
Worldwide Research and Development Expense [Member]
       
Restructuring charges(a):        
Total additional depreciation––asset restructuring 29 [3] 3 [3] 29 [3] 94 [3]
Implementation costs recorded in our condensed consolidated statements of income as follows(d):        
Total implementation costs 16 [4] 7 [4] 27 [4] 9 [4]
Acquisition-related Costs [Member]
       
Restructuring Cost and Reserve [Line Items]        
Restructuring and related cost, expected cost     450  
Business Restructuring Reserves [Member]
       
Restructuring Cost and Reserve [Line Items]        
Restructuring and related cost, expected cost     350  
Commercial Real Estate [Member]
       
Restructuring Cost and Reserve [Line Items]        
Restructuring and related cost, expected cost     900  
Facility Closing [Member]
       
Restructuring Cost and Reserve [Line Items]        
Restructuring and related cost, expected cost     $ 1,500  
[1] In the six months ended June 29, 2014, Employee terminations represent the expected reduction of the workforce by approximately 300 employees, mainly in manufacturing and sales.The restructuring charges in 2014 are associated with the following:•For the three months ended June 29, 2014, the Global Innovative Pharmaceutical segment (GIP) ($9 million), the Global Established Pharmaceutical segment (GEP) ($24 million), the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($6 million), Worldwide Research and Development and Medical ($8 million), manufacturing operations ($12 million) and Corporate ($7 million).•For the six months ended June 29, 2014, the Global Innovative Pharmaceutical segment (GIP) ($11 million), the Global Established Pharmaceutical segment (GEP) ($31 million), the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($6 million), Worldwide Research and Development and Medical ($9 million), manufacturing operations ($38 million) and Corporate ($11 million).The restructuring charges in 2013 are associated with the following:•For the three months ended June 30, 2013, total operating segments ($54 million), Worldwide Research and Development and Medical ($12 million), manufacturing operations ($80 million) and Corporate ($4 million). •For the six months ended June 30, 2013, total operating segments ($67 million), Worldwide Research and Development and Medical ($15 million), manufacturing operations ($82 million) and Corporate ($81 million).At the beginning of fiscal 2014, we revised our operating segments and are unable to identify these prior-period restructuring charges to the new individual segments.
[2] Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes.
[3] Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[4] Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.